Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 7;62(3):356-361.
doi: 10.2478/rjim-2024-0021. Print 2024 Sep 1.

Treatment-Refractory Eosinophilic Esophagitis Successfully Managed with benralizumab: A Case Presentation and literature review

Grigorios Petrousis  1 , Pavlos Retsas  2 , Simone Ignatova  3 , Dimitrios Karapiperis  1
Affiliations
Free article
Review

Treatment-Refractory Eosinophilic Esophagitis Successfully Managed with benralizumab: A Case Presentation and literature review

Grigorios Petrousis et al. Rom J Intern Med. .
Free article

Abstract

Eosinophilic Esophagitis is a widely-recognized immune-mediated esophagus disease with distinct clinical and histopathological features, exhibiting an increased global incidence. Therapeutic options encompass either dietary measures or pharmacological approaches, including proton pump inhibitors and topical corticosteroids. The use of monoclonal antibodies is currently under comprehensive evaluation, with a plethora of ongoing clinical trials designed to determine their clinical efficacy. The present case report demonstrates an exceptional case of refractory Eosinophilic Esophagitis, unresponsive to conventional treatment, achieving both clinical and histopathological remission subsequent to initiation of benralizumab treatment. Concurrently, our case underscores the necessity for continued research in the field of monoclonal antibodies for their use as a future treatment approach against Eosinophilic Esophagitis.

Keywords: benralizumab; case report; dysphagia; eosinophilic esophagitis; monoclonal antibodies.

PubMed Disclaimer

References

    1. SYVERSON E. P., HAIT E. Update on Emerging Pharmacologic Therapies for Patients With Eosinophilic Esophagitis, Gastroenterol. Hepatol., vol. 18, no. 4, pp. 207 – 212, Apr. 2022.
    1. COLLINS M. H., CAPOCELLI K., YANG G.-Y. Eosinophilic Gastrointestinal Disorders Pathology, Front. Med., vol. 4, p. 261, 2017.
    1. ALLIN K. H., POULSEN G., MELGAARD D., FRANDSEN T., JESS T., KRARUP A. L. Eosinophilic oesophagitis in Denmark: Population-based incidence and prevalence in a nationwide study from 2008 to 2018, United Eur. Gastroenterol. J., vol. 10, no. 7, pp. 640 – 650, Sep. 2022.
    1. MUIR A., FALK G. W. Eosinophilic Esophagitis: A Review, JAMA, vol. 326, no. 13, pp. 1310 – 1318, Oct. 2021.
    1. FEO-ORTEGA S., LUCENDO A. J. Evidence-based treatments for eosinophilic esophagitis: insights for the clinician, Ther. Adv. Gastroenterol., vol. 15, p. 17562848211068665, 2022.

Substances

LinkOut - more resources